Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.

Lesort M, Lee M, Tucholski J, Johnson GV.

J Biol Chem. 2003 Feb 7;278(6):3825-30. Epub 2002 Nov 27.

PMID:
12458211
[PubMed - indexed for MEDLINE]
Free Article
2.

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.

Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM.

J Neurochem. 2004 Oct;91(2):413-22.

PMID:
15447674
[PubMed - indexed for MEDLINE]
3.
4.

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L.

Nat Med. 2002 Feb;8(2):143-9. Erratum in: Nat Med 2002 Mar;8(3):303.

PMID:
11821898
[PubMed - indexed for MEDLINE]
5.

Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner.

Tucholski J, Johnson GV.

J Neurochem. 2002 May;81(4):780-91.

PMID:
12065637
[PubMed - indexed for MEDLINE]
6.

Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells.

Ientile R, Campisi A, Raciti G, Caccamo D, Currò M, Cannavò G, Li Volti G, Macaione S, Vanella A.

J Neurosci Res. 2003 Oct 1;74(1):52-9.

PMID:
13130505
[PubMed - indexed for MEDLINE]
7.

Therapeutic effects of cystamine in a murine model of Huntington's disease.

Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ.

J Neurosci. 2002 Oct 15;22(20):8942-50.

PMID:
12388601
[PubMed - indexed for MEDLINE]
Free Article
8.

Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.

Lesort M, Tucholski J, Zhang J, Johnson GV.

J Neurochem. 2000 Nov;75(5):1951-61.

PMID:
11032884
[PubMed - indexed for MEDLINE]
9.

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR.

J Neurochem. 2005 Oct;95(1):210-20.

PMID:
16181425
[PubMed - indexed for MEDLINE]
10.

Caspase inhibition: a potential therapeutic strategy in neurological diseases.

Rideout HJ, Stefanis L.

Histol Histopathol. 2001 Jul;16(3):895-908. Review.

PMID:
11510981
[PubMed - indexed for MEDLINE]
11.

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM.

Nature. 1999 May 20;399(6733):263-7.

PMID:
10353249
[PubMed - indexed for MEDLINE]
12.

Caspase 3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12 cells.

Jiang D, Jha N, Boonplueang R, Andersen JK.

J Neurochem. 2001 Mar;76(6):1745-55.

PMID:
11259492
[PubMed - indexed for MEDLINE]
13.

Caspases in Huntington's disease.

Sanchez Mejia RO, Friedlander RM.

Neuroscientist. 2001 Dec;7(6):480-9. Review.

PMID:
11765125
[PubMed - indexed for MEDLINE]
14.

Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells.

Mao Z, Choo YS, Lesort M.

Eur J Neurosci. 2006 Apr;23(7):1701-10.

PMID:
16623826
[PubMed - indexed for MEDLINE]
15.

Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells.

Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D.

Circ Res. 2004 Feb 20;94(3):370-6. Epub 2003 Dec 18.

PMID:
14684629
[PubMed - indexed for MEDLINE]
Free Article
16.

Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.

Asakura T, Sawai T, Hashidume Y, Ohkawa Y, Yokoyama S, Ohkawa K.

Br J Cancer. 1999 May;80(5-6):711-5.

PMID:
10360648
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells.

Wang GH, Mitsui K, Kotliarova S, Yamashita A, Nagao Y, Tokuhiro S, Iwatsubo T, Kanazawa I, Nukina N.

Neuroreport. 1999 Aug 20;10(12):2435-8.

PMID:
10574348
[PubMed - indexed for MEDLINE]
18.

Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53.

Mathiasen IS, Lademann U, Jäättelä M.

Cancer Res. 1999 Oct 1;59(19):4848-56.

PMID:
10519395
[PubMed - indexed for MEDLINE]
Free Article
19.

Cytochrome C and caspase-9 expression in Huntington's disease.

Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ.

Neuromolecular Med. 2002;1(3):183-95.

PMID:
12095160
[PubMed - indexed for MEDLINE]
20.

Temporal relationships between ceramide production, caspase activation and mitochondrial dysfunction in cell lines with varying sensitivity to anti-Fas-induced apoptosis.

Rodriguez-Lafrasse C, Alphonse G, Broquet P, Aloy MT, Louisot P, Rousson R.

Biochem J. 2001 Jul 15;357(Pt 2):407-16.

PMID:
11439090
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk